Fixed-Duration Ibrutinib-Venetoclax in Patients with Chronic Lymphocytic Leukemia and Comorbidities
Kater AP, et al.
NEJM Evidence
May 2022
Authors and Affiliates
Arnon P. Kater, M.D., Ph.D.,1 Carolyn Owen, M.D.,2 Carol Moreno, M.D.,3 George Follows, B.M.Bch., Ph.D.,4 Talha Munir, M.B.B.S.,5 Mark-David Levin, M.D.,6 Ohad Benjamini, M.D.,7 Ann Janssens, M.D., Ph.D.,8 Anders Osterborg, M.D., Ph.D.,9 Tadeusz Robak, M.D., Ph.D.,10 Martin Simkovic, M.D., Ph.D.,11 Don Stevens, M.D.,12 Sergey Voloshin, M.D., Ph.D.,13 Vladimir Vorobyev, Ph.D.,14 Loic Ysebaert, M.D., Ph.D.,15 Rui Qin, Ph.D.,16 Andrew J. Steele, Ph.D.,17 Natasha Schuier, M.D.,18 Kurt Baeten, Ph.D.,19 Donne Bennett Caces, M.D., Ph.D.,16 and Carsten U. Niemann, M.D., Ph.D.,20 for the GLOW Investigators
1 Amsterdam University Medical Centers, Cancer Center Amsterdam, University of Amsterdam, on behalf of the HOVON CLL Working Group, Amsterdam 2 Tom Baker Cancer Centre, Calgary, Alberta, Canada 3 Hospital de la Santa Creu i Sant Pau, Autonomous University of Barcelona, Barcelona 4 Addenbrooke’s Hospital, Cambridge, UK 5 St James’s Hospital, Leeds, UK 6 Albert Schweitzer Hospital, Dordrecht, Netherlands 7 Sheba Medical Center, Ramat Gan, Israel 8 Universitaire Ziekenhuizen Leuven, Leuven, Belgium 9 Karolinska University Hospital, Stockholm 10 Medical University of Łodz, Copernicus Memorial Hospital, Łodz, Poland 11 University Hospital Hradec Kralove, Hradec Kralove, Czech Republic 12 Norton Cancer Institute, Louisville, KY 13 Russian Scientific Research Institute of Hematology and Transfusiology, St. Petersburg, Russia 14 S.P. Botkin Moscow City Clinical Hospital, Moscow 15 Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France
16 Janssen Research & Development, Raritan, NJ 17 Janssen Research & Development, San Diego, CA 18 Janssen Research & Development, Dusseldorf, Germany 19 Janssen Research & Development, Beerse, Belgium
20 Rigshospitalet Copenhagen University Hospital, Copenhagen